Appointments at Sanofi-Aventis, RXi Pharmaceuticals and Vivus – People on the move
RXi Pharmaceuticals has appointed Noah Beerman as president and CEO. Beerman’s appointment is part of a planned succession as RXi moves from the research stage to product development and partnerships.
He has more than 25 years experience in the biopharm sector at companies including Indevus Pharmaceuticals, Creative BioMolecules, Sandoz AG and Repligen.
Peter Tam has been appointed as president of Vivus. Tam has worked at Vivus for the past 16 years and prior to this held positions at Genentech and Xoma. He has also been appointed the the board of directors.
Sanofi-Aventis has made changes to its leadership to create a team that can transform the company “into a global diversified healthcare company”. Hanspeter Spek’s role has expanded beyond pharmaceuticals following his appointment as president, global operations.
To drive changes in the big pharma’s R&D Marc Cluzel has been appointed as executive vice president (VP), research and development and, recognising the importance of Sanofi Pasteur, Wayne Pisano, senior VP, vaccines has joined the executive committee.
John Dawley has been appointed as VP of sales for North America at Veeva Systems. Dawley spent almost 10 years at Dendrite International and has also worked at other companies in the life sciences sector.
NeurogesX has made appointments in preparation for a possible US product launch. Timothy Arendt has been appointed as VP sales, Amy Cavers has joined the company as senior director of marketing and Linda Schook has been named director of commercial operations.
